Cobomarsen

N/A

Report date: 2025/10/06 20:00:47
NME

Base Information

Drug NameCobomarsen
Drug Alias NameMRG-106LNA-antimiR-155
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionmicroRNA-155 inhibitors
TargetsmicroRNA-155
Therapy Area/IndicationsMycosis FungoidesLymphoma, T-Cell, CutaneousLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMiragen Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViridian Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMycosis FungoidesLymphoma, T-Cell, CutaneousLymphoma, Large B-Cell, Diffuse +[5] 

Other Information

ATC CodeN/A
Related LinksN/A